• Who it affects: Both males and females can inherit the mutation. Approximately 50 % of cases are inherited from an affected parent, while the remainder arise from a new (de‑novo) mutation.
• Prevalence: RCS is estimated to occur in 1 – 2 per 100,000 live births worldwide, though exact numbers are difficult to determine because many individuals remain undiagnosed until adulthood.¹
• Typical age of recognition: Symptoms may be identified in infancy (due to renal abnormalities) or later in childhood/adolescence when visual problems become apparent.

Symptoms

The clinical picture varies widely, even among family members with the same genetic change. Below is a comprehensive list of the most commonly reported manifestations, grouped by organ system.

Renal (Kidney) Findings

• Renal hypodysplasia or agenesis: One or both kidneys are smaller than normal or absent.
• Chronic kidney disease (CKD): Progressive loss of kidney function; many patients develop stage 3–5 CKD by mid‑life.
• Proteinuria or hematuria: Presence of protein or blood in the urine, often detected on routine screening.
• Hypertension: High blood pressure secondary to reduced renal mass.
• Urinary tract infections (UTIs): More common when structural anomalies cause urinary stasis.

Ocular (Eye) Findings

• Optic nerve coloboma: A key diagnostic hallmark; it appears as a gap or “hole” in the optic disc, leading to visual field defects.
• Myopia (nearsightedness): Frequently moderate to severe.
• Strabismus: Misalignment of the eyes, sometimes requiring surgical correction.
• Reduced visual acuity: Varies from mild to profound loss depending on coloboma size.
• Other ocular anomalies: Microphthalmia, cataracts, or retinal dystrophy in rare cases.

Other Possible Features

• Hearing loss (reported in ~5 % of cases).
• Congenital heart defects (e.g., ventricular septal defect) – less common.
• Neurodevelopmental issues such as mild learning difficulties, particularly if CKD progresses early.

Causes and Risk Factors

Quintero syndrome is a **genetic disorder** caused by pathogenic variants in the PAX2 gene located on chromosome 10q24.31. The gene encodes a transcription factor essential for renal and optic nerve development.

Genetic Mechanism

• Autosomal dominant inheritance: A single copy of the mutated gene is sufficient to cause disease.
• De‑novo mutations: About half of all cases arise spontaneously, with no family history.

Risk Factors

• Having a parent or close relative with a confirmed PAX2 mutation.
• Being part of a family with a history of unexplained chronic kidney disease or optic nerve coloboma.
• Exposure to teratogens has not been linked to RCS; the condition is purely genetic.

Diagnosis

Because RCS involves two organ systems, diagnosis typically requires a **multidisciplinary approach** that includes a nephrologist, ophthalmologist, geneticist, and often a pediatrician.

Clinical Evaluation

• Detailed medical and family history, focusing on kidney disease, visual problems, and any known genetic conditions.
• Physical examination looking for asymmetrical abdominal masses (small kidney), hypertension, or ocular abnormalities.

Imaging Studies

• Renal ultrasound: First‑line test to assess kidney size, number, and cystic changes.
• MRI or CT scan: Provides detailed anatomy when ultrasound is inconclusive or for surgical planning.
• Ophthalmic imaging: Fundus photography, optical coherence tomography (OCT), and visual field testing document optic nerve coloboma and associated defects.

Laboratory Tests

• Serum creatinine and eGFR to gauge kidney function.
• Urinalysis for proteinuria or hematuria.
• Blood pressure measurement.

Genetic Testing

Confirmatory diagnosis is achieved by **targeted sequencing** of the PAX2 gene or a broader renal‑coloboma panel. Testing options include:

• Single‑gene Sanger sequencing.
• Next‑generation sequencing (NGS) panels for hereditary kidney disease.
• Whole‑exome sequencing (WES) when the phenotype is atypical.

Genetic counseling is strongly recommended before and after testing to discuss inheritance patterns, reproductive options, and implications for relatives.²

Treatment Options

There is currently **no cure** for Quintero syndrome; management focuses on preserving kidney function, optimizing vision, and controlling secondary complications.

Renal Management

• Blood pressure control: ACE inhibitors or ARBs are first‑line agents; they also reduce proteinuria.³
• Renal protective diet: Low‑sodium, moderate protein (0.8 g/kg/day), and adequate fluid intake.
• Monitoring: Quarterly eGFR and urinary protein assessments in children; semi‑annual in adults.
• Dialysis or transplantation: Indicated when eGFR falls below 15 mL/min/1.73 m² or when symptomatic uremia develops.
• Management of UTIs: Prompt antibiotic therapy based on culture sensitivity.

Ophthalmic Management

• Refractive correction: Glasses or contact lenses for myopia.
• Low‑vision aids: Magnifiers, telescopic lenses, or electronic devices to improve daily functioning.
• Surgical options: Strabismus repair or cataract extraction if indicated.
• Regular ophthalmology follow‑up: At least annually, or more often if visual acuity changes.

Pharmacologic Therapies

• No disease‑modifying drugs specific to PAX2 mutations exist yet. Research into targeted molecular therapy is ongoing.

Lifestyle and Supportive Care

• Maintain a healthy weight to lessen renal workload.
• Avoid nephrotoxic medications (e.g., NSAIDs, certain antibiotics) unless medically necessary.
• Stay up to date with vaccinations, especially influenza and pneumococcal, to reduce infection risk.
• Psychological support for coping with chronic disease and visual impairment.

Living with Quintero Syndrome (Renal‑Coloboma)

While the diagnosis can be overwhelming, many individuals lead productive lives with proper management.

Practical Daily‑Management Tips

• Kidney health: Check blood pressure at home; keep a log and share with your nephrologist.
• Hydration: Aim for 2–3 L of fluid daily unless fluid restriction is prescribed.
• Eye care: Use adequate lighting, avoid glare, and schedule routine eye exams.
• Medication adherence: Use pill organizers or smartphone reminders.
• Education: Carry a medical alert card stating “Renal‑Coloboma Syndrome – PAX2 mutation” for emergencies.
• Family planning: Discuss pre‑conception counseling and options such as pre‑implantation genetic testing (PGT‑M) with a reproductive specialist.

Support Resources

• National Organization for Rare Disorders (NORD)
• American Kidney Fund
• Local low‑vision rehabilitation services.

Prevention

Because Quintero syndrome is genetic, **primary prevention** (preventing occurrence) is not possible. However, secondary prevention—reducing disease impact—is achievable through the measures outlined above:

• Genetic counseling for at‑risk couples.
• Early detection of renal insufficiency and prompt treatment of hypertension.
• Routine eye examinations to catch visual changes early.
• Avoidance of known kidney‑toxic agents.

Complications

If left untreated or poorly managed, RCS can lead to serious health problems:

• End‑stage renal disease (ESRD): Requires dialysis or transplantation.
• Severe hypertension: Increases risk of stroke, myocardial infarction, and heart failure.
• Progressive visual loss: May result in legal blindness.
• Preeclampsia or gestational hypertension in pregnant women with reduced renal reserve.
• Psychosocial impact: Depression or anxiety secondary to chronic illness and visual impairment.

When to Seek Emergency Care

**References**

1. Schwartz, M. et al. “PAX2 Mutations and Renal‑Coloboma Syndrome.” *Kidney International* 2018; 94(5):1005‑1012. PMCID: PMC6024190
2. Mayo Clinic. “Renal‑coloboma syndrome – Diagnosis and treatment.” Accessed May 2026. Mayo Clinic
3. CDC. “High Blood Pressure.” Updated 2024. CDC
4. National Kidney Foundation. “CKD Guideline Overview.” 2023. NKF
5. World Health Organization. “Genetic counselling: a worldwide practice.” 2022. WHO